Measure Abbreviation
NMB-02
Data Collection Method

This measure is calculated based on data extracted from the electronic medical record combined with administrative data sources such as professional fee and discharge diagnoses data.  This measure is explicitly not based on provider self-attestation.

Measure Type
Process
Description

Administration of Neostigmine, Sugammadex, and/or Edrophonium before extubation for cases with non-depolarizing neuromuscular blockade.

Measure Time Period

Anesthesia Start to Earliest Extubation

Inclusions

All patients that have received either by bolus or infusion a non-depolarizing neuromuscular blocker (NMB) AND were extubated post-operatively.  The following NMBs were included:

  • Atracurium
  • Cisatracurium
  • Pancuronium
  • Rocuronium
  • Vecuronium
Exclusions
  • ASA 5 and 6 cases.
  • Patients that were not extubated in the immediate post-operative period.
  • Patients not given NMBs.
  • Cardiac surgery without pump (CPT: 00560)
  • Cardiac surgery with pump and <1 year old (CPT: 00561)
  • Cardiac surgery with pump and > 1 year old (CPT: 00562)
  • Cardiac surgery with hypothermic arrest (CPT: 00563)
  • CABG with pump (CPT: 00567)
  • Heart Transplant (CPT: 00580)
  • Cases where patients (age > 12) received defasciculating doses of
  • Vecuronium ≤ 1mg
  • Cisatracurium ≤ 2mg
  • Rocuronium  ≤ 10 mg
  • Cases performed by cardiac surgical service: MPOG concept 80005.
  • Any cardiac case with an intraoperative note mapped to one of the following MPOG Concepts:
    • 50399    Cardiopulmonary bypass -- aortic clamp on/off note
    • 50409    Cardiopulmonary bypass terminated
    • 50410    Cardiopulmonary bypass initiated (full)
    • 50416    Cardiopulmonary bypass -- crossclamp and circulatory arrest time totals
    • 50417    Cardiopulmonary bypass -- Access cannula removed note
    • 50714    Cardiopulmonary bypass - Bypass start / stop event
Success

Documentation of neostigmine, Sugammadex, and/or edrophonium before earliest extubation.

OR

A period of greater than 3 hours exists between last dose of non-depolarizing medication and extubation for patients ≥ 12 years old.

OR

A period of greater than 2 hours exists between last dose of non-depolarizing medication and extubation for patients <12 years old.

OR

An acceleromyography ratio of ≥ 0.9 documented after last dose of NMB and before earliest extubation.

Other Measure Build Details
Responsible Provider

The provider(s) signed in at time of earliest extubation.

Threshold
90%
MPOG Concept IDs Required

Neuromuscular Blocker Medications

Reversal Agents

 

Extubation

Train of Four

 

10043

Atracurium

10170

Edrophonium

50127

Intubation Extubated Awake or Deep

3485

Train-of-four (Acceleromyography)

10129

Cisatracurium

10315

Neostigmine

50202

Emergence- Patient Extubated

 

10344

Pancuronium

10739

Sugammadex

50145

Airway – Laryngeal mask airway removed (deep or awake)

 

10393

Rocuronium

 

10446

Vecuronium

 

Data Diagnostics Affected
  • Percentage of Cases with a Non-Depolarizing NMB Administration
  • Percentage of Cases with an Extubation Note
  • Percentage of Cases with Neuromuscular Blocker Reversal Agents Administered
  • Percentage of Medications with a Meaningful Medication Mapping
  • Percentage of Cases with any Staff Tracking
  • Percentage of Anesthesia Provider Sign-Ins that are Timed
Rationale

Postoperative residual neuromuscular blockade can lead to significant complications.1,2  Several studies have found associations between the use of neuromuscular blockade agents (NMBA) and residual neuromuscular blockade in the recovery room.   Adverse postoperative respiratory outcomes are even more frequent when patients receive NMBA and reversal agents are not used.  A mainstay of residual blockade prevention continues to be monitoring to allow for detection, and use of reversal agents like neostigmine and sugammadex.3-5 Due to variability in duration of muscle relaxants, even in defasciculating doses, we recommend that TOF is monitored when any non-depolarizing neuromuscular blockers are administered.

References
  1. McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent Association between Intermediate-acting Neuromuscular-blocking Agents and Postoperative Respiratory Complications. Anesthesiology. 2015;122(6):1201-1213.
  2. Murphy GS, Szokol JW, Avram MJ, et al. Residual Neuromuscular Block in the Elderly: Incidence and Clinical Implications. Anesthesiology. 2015;123(6):1322-1336.
  3. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesthesia and analgesia. 2010;111(1):129-140.
  4. Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia. Anesthesiology. 2016;125(4):647-655.
  5. Lien CA, Kopman AF. Current recommendations for monitoring depth of neuromuscular blockade. Current opinion in anaesthesiology. 2014;27(6):616-622.